Text Size

PET Imaging in Parkinson Disease Dementia

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2011 by Washington University School of Medicine.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Washington University School of Medicine
ClinicalTrials.gov Identifier:
NCT01052350
First received: January 15, 2010
Last updated: March 2, 2011
Last verified: March 2011
History of Changes
  Purpose

The purpose of this study is to use a brain imaging method called PIB PET to determine dementia subtypes in patients with Parkinson's disease. The ultimate goal of this project is to be able to identify individuals with PD who are at risk of developing dementia, and to distinguish the underlying cause of dementia.


Condition
Parkinson's Disease

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Use of PIB PET Imaging to Evaluate Dementia Subtypes in Patients With Parkinson Disease

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Washington University School of Medicine:

Biospecimen Retention:   Samples With DNA

whole blood


Estimated Enrollment: 125
Study Start Date: August 2006
Groups/Cohorts
Parkinson disease
individuals with Parkinson disease
healthy control
individuals without Parkinson disease

  Eligibility

Ages Eligible for Study:   55 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Participants with and without Parkinson disease will be recruited from the Movement Disorders Center at Washington University, the St. Louis metro area, and throughout the midwest region.

Criteria

Inclusion Criteria:

  • PD patients must exhibit three of the following cardinal signs: rest tremor, rigidity, bradykinesia, or postural instability; or two of these features with one of the first three displaying asymmetry.

Exclusion Criteria:

  • history of head trauma, major neurological or psychiatric diseases other than Parkinson disease and dementia, e.g. stroke, multiple sclerosis, depression or schizophrenia
  • severe systemic diseases
  • inability to lie still for 90 minutes
  • metallic implants, pacemakers, or any other contraindication to MRI
  • refusal to consent to brain donation
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01052350

Contacts
Contact: Johanna Hartlein, MSN, APN 314-362-0420 johanna@npg.wustl.edu

Locations
United States, Missouri
NeuroClinical Research Unit (NCRU), Washington University School of Medicine Recruiting
St. Louis, Missouri, United States, 63110
Contact: Johanna Hartlein, MSN, APN     314-362-0240     johanna@npg.wustl.edu    
Sponsors and Collaborators
Washington University School of Medicine
Investigators
Principal Investigator: Joel S. Perlmutter, MD Washington University School of Medicine
  More Information

No publications provided

Responsible Party: Joel S. Perlmutter, Washington University School of Medicine
ClinicalTrials.gov Identifier: NCT01052350     History of Changes
Other Study ID Numbers: 06-0706
Study First Received: January 15, 2010
Last Updated: March 2, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by Washington University School of Medicine:
Parkinson disease
PET imaging
PIB
dementia

Additional relevant MeSH terms:
Dementia
Parkinson Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
 Mental Disorders
Parkinsonian Disorders
Basal Ganglia Diseases
Movement Disorders
Neurodegenerative Diseases

ClinicalTrials.gov processed this record on May 22, 2013